While the profits are low, something is better than nothing, so they stay in the market. "On the positive side," says Song, "the more financially squeezed the National Health Insurance system is, the greater the opportunity for generic drugs, since hospitals struggling to meet budgetary constraints will have to turn to generic drugs, which are much cheaper than the brand-name products."
「往好處想，健保的財務壓力越大，學名藥的擴展空間也就愈大，因為各大醫院在總額預算的限制下，勢必傾向採購價格遠比原廠藥便宜的學名藥，」宋智仁分析。